GnRH Agonist and Intrauterine Insemination

Effect of GnRH Agonist Administration at the Time of Implantation in Intrauterine Insemination Cycles: A Randomized Controlled Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00503217

Enrollment

Unknown

Registered

2007-07-18

Start date

2005-02-28

Completion date

2007-12-31

Last updated

2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine Insemination

Keywords

intrauterine insemination, GnRH agonist, implantation

Brief summary

The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Interventions

DRUGTryptorelin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

SINGLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Yes

Inclusion criteria

* Women \< 38 years old * Bilateral tubal patency confirmed by hysterosonography * Normal ultrasound scan of uterus and ovaries * Normal day 3 basal hormones * Motile sperm count after capacitation ≥ 3 mill/ml

Exclusion criteria

* Endometriosis * Polycystic ovary syndrome * Uterine disease (polyps, myomas and müllerian diseases)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026